340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed

Maureen Testoni, the president and CEO of 340B Health celebrated J&J’s retreat from a 340B rebate proposal in an Oct. 9 RACmonitor op-ed.
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions

Two community health centers argued in a Sept. 30 filing with the U.S. 2nd Circuit Court of Appeals that diabetes drugmakers colluded to place contract pharmacy restrictions.
Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

340B-IRA interactions
CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed

Sally Pipes, the president and CEO of the drug-industry funded Pacific Research Institute, criticized pushback that led Johnson & Johnson to forgo its plans to implement a 340B rebate model in an Oct. 7 Forbes op-ed.
The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS’ MDRP Final Rule May Impact 340B Covered Drugs, Attorneys Say

CMS' recently-released MDRP final rule may affect 340B covered drugs and draw litigation.
A new federal regulation updating the definition of a covered outpatient drug could change the number of drugs covered under [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Announces Specialty Pharmacy Senderra No Longer Eligible to Dispense Asthma Drug

GSK headquarters
Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.
Specialty pharmacy Senderra Rx will no longer dispense GlaxoSmithKline’s (GSK’s) asthma treatment Nucala, the drug manufacturer announced on industry vendor [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Amgen Announces NDC Change for Osteoporosis Drug

Amgen announced a change to the national drug code for its osteoporosis drug, Prolia.
Drugmaker Amgen announced a change to the national drug code (NDC) for its osteoporosis drug, Prolia. The California-based drug giant [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Arkansas Begins Enforcement Against AstraZeneca for Allegedly Violating Contract Pharmacy Access Law

The Arkansas Insurance Department held a preliminary hearing with attorneys for AstraZeneca on Oct. 1.
Arkansas officials initiated enforcement proceedings earlier this week against AstraZeneca for allegedly violating a state law that prohibits drugmaker 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Finalizes Next Medicare Drug Negotiation Guidance Without Resolving Key Concerns of 340B Stakeholders

The AHA raised concerns that October 2024 federal guidance on Medicare drug price negotiations may allow drugmakers to “wrongly justify fundamental changes to the 340B program.”
Federal regulators issued final guidance for the next round of Medicare drug price negotiations yesterday but did not propose remedies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live